Perjeta Approved for Neoadjuvant Treatment of Early Stage HER2-Positive Breast Cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Perjeta® (pertuzumab) for the neoadjuvant treatment of early stage breast cancer before surgery. This is the first drug approved for the neoadjuvant treatment of breast cancer.   Breast …

Source: Breast Cancer News

Leave a Reply

Your email address will not be published. Required fields are marked *